An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
Public ClinicalTrials.gov record NCT03414983. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
Study identification
- NCT ID
- NCT03414983
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 196 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Oxaliplatin Drug
- Leucovorin Drug
- Fluorouracil Drug
- Bevacizumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2018
- Primary completion
- Jan 31, 2021
- Completion
- Dec 27, 2022
- Last update posted
- Nov 17, 2023
2018 – 2022
United States locations
- U.S. sites
- 35
- U.S. states
- 21
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uab Comprehensive Cancer Center | Birmingham | Alabama | 35294-3300 | — |
| Local Institution - 0004 | Los Angeles | California | 90033 | — |
| Local Institution - 0010 | Aurora | Colorado | 80045 | — |
| Local Institution - 0027 | Denver | Colorado | 80218 | — |
| Local Institution - 0020 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0039 | Miami | Florida | 33176 | — |
| Local Institution - 0047 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0033 | Arlington Heights | Illinois | 60005 | — |
| Local Institution - 0044 | Indianapolis | Indiana | 46260 | — |
| Local Institution - 0021 | Bethesda | Maryland | 20817 | — |
| Local Institution - 0003 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0049 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0052 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0053 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0035 | Minneapolis | Minnesota | 55404 | — |
| Local Institution - 0002 | Rochester | Minnesota | 55905 | — |
| Local Institution - 0032 | Papillion | Nebraska | 68046 | — |
| Local Institution - 0029 | Henderson | Nevada | 89074 | — |
| Local Institution - 0031 | Johnson City | New York | 13790 | — |
| Local Institution - 0046 | New York | New York | 10016 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28262 | — |
| Local Institution - 0038 | Portland | Oregon | 97227 | — |
| Local Institution - 0005 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0024 | Pittsburgh | Pennsylvania | 15212 | — |
| Local Institution - 0023 | Sioux Falls | South Dakota | 57104 | — |
| Erlanger Oncology & Hematology - Univ. of TN | Chattanooga | Tennessee | 37403 | — |
| Local Institution - 0019 | Nashville | Tennessee | 37203 | — |
| Local Institution - 0026 | Bedford | Texas | 76022 | — |
| Local Institution - 0034 | Dallas | Texas | 75246 | — |
| Local Institution - 0037 | Fort Worth | Texas | 76104 | — |
| Local Institution - 0040 | San Antonio | Texas | 78217 | — |
| Local Institution - 0036 | Tyler | Texas | 75702 | — |
| Local Institution - 0025 | Richmond | Virginia | 23229 | — |
| Local Institution - 0028 | Roanoke | Virginia | 24014 | — |
| Local Institution - 0006 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03414983, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2023 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03414983 live on ClinicalTrials.gov.